High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 65, Issue 7, 2016, Pages 813-819

  Kalathil, Suresh Gopi ^a   Thanavala, Yasmin ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CITIM 2015; Hepatocellular cancer; Immunosuppression; Myeloid derived suppressor cells; PD 1+ T cells; Regulatory T cells

Indexed keywords

ARGINASE 1; CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FETOPROTEIN; GAMMA INTERFERON; GLYPICAN 3; GRANZYME B; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; NITRIC OXIDE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; AUTOIMMUNITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84959106624     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1810-0     Document Type: Review

References (47)

1. Schrader J (2013) The role of MDSCs in hepatocellular carcinoma—in vivo veritas? J Hepatol 59:921–923
2. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A et al (2013) The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013:187204. doi:10.1155/2013/187204
3. Cabrera R, Szabo G (2013) Another armed CD4(+) T cell ready to battle hepatocellular carcinoma. Hepatology 58:1–3
4. + cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 58:139–149
5. Pastille E, Bardini K, Fleissner D, Adamczyk A, Frede A, Wadwa M et al (2014) Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer Res 74:4258–4269
6. Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF (2015) The yin and yang of evasion and immune activation in HCC. J Hepatol 62:1420–1429
7. + regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol 29:851–859
8. Zhang X, Kelaria S, Kerstetter J, Wang J (2015) The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J Gastrointest Oncol 6:307–313
9. Kondo Y, Shimosegawa T (2015) Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs. Int J Mol Sci 16:3307–3322
10. +CD127 (low) regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma. Front Immunol 6:49. doi:10.3389/fimmu.2015.00049
11. + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res 17:34. doi:10.1186/s13058-015-0541-z
12. Zhang D, Chen Z, Wang DC, Wang X (2015) Regulatory T cells and potential inmmunotherapeutic targets in lung cancer. Cancer Metastasis Rev 34:277–290
13. Yan F, Du R, Wei F, Zhao H, Yu J, Wang C et al (2015) Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. Cancer Immunol Immunother 64:1475–1485
14. Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M et al (2015) Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760). J Thorac Oncol 10:74–83
15. Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13:739–752
16. Stromnes IM, Greenberg PD, Hingorani SR (2014) Molecular pathways: myeloid complicity in cancer. Clin Cancer Res 20:5157–5170
17. Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM et al (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769–1781
18. + cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 73:3877–3887
19. Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H et al (2015) Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21:30–38
20. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN et al (2012) IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1:1460–1468
21. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM et al (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20:1601–1609
22. + HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 62:1421–1430
23. Napolitano M, D’Alterio C, Cardone E, Trotta AM, Pecori B, Rega D et al (2015) Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget 6:8261–8270
24. Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor SP (2014) Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 63:1177–1187
25. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y (2013) Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 73:2435–2444
26. Medina-Echeverz J, Eggert T, Han M, Greten TF (2015) Hepatic myeloid-derived suppressor cells in cancer. Cancer Immunol Immunother 64:931–940
27. Diaz-Montero CM, Finke J, Montero AJ (2014) Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 41:174–184
28. Zhu Y, Hawkins WG, DeNardo DG (2015) Regramming myeloid responses to improve cancer immunotherapy. Oncoimmunology 4:e974399. doi:10.4161/2162402X.2014.974399
29. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074
30. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030
31. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144
32. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
33. Andersen MH (2014) The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 28:1784–1792
34. Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S (2013) Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol 191:2829–2836
35. Ostrand-Rosenberg S, Horn LA, Haile ST (2014) The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol 193:3835–3841
36. Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM et al (2015) Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther 23:1630–1640
37. Schmidt N, Flecken T, Thimme R (2014) Tumor-associated antigen specific CD8 T cells in hepatocellular carcinoma—a promising target for immunotherapy. Oncoimmunology 3:e954919. doi:10.4161/21624011.2014.954919
38. Hato T, Goyal L, Greten TF, Duda DG, Zhu AX (2014) Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 60:1776–1782
39. Lugade AA, Kalathil S, Miller A, Iyer R, Thanavala Y (2013) High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored? Oncoimmunology 2:e24679. doi:10.4161/onci.24679
40. Yano H, Thakur A, Tomaszewski EN, Choi M, Deol A, Lum LG (2014) Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med 12:191. doi:10.1186/1479-5876-12-191
41. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T et al (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2:632–642
42. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373:23–34
43. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP et al (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341
44. + T-cell responses in hepatocellular carcinoma. Hepatology 59:1415–1426
45. Zhao HQ, Li WM, Lu ZQ, Yao YM (2014) Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 20:7971–7978
46. Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A et al (2015) Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother 64:1271–1286
47. Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC et al (2013) Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer 133:2895–2902